Fig. 8.
![Fig. 8. Reduced capacity of CML-DCs to migrate. / DCs were generated from healthy individuals (■ [A-B]; dotted lines [C-D]) and from CML patients (▪ [A-B]; solid lines [C-D]): patient 1 (A,C) and patient 6 (B,D). (A-B) Immature DCs were added to the 8 μm pore size filter in a transwell cell culture chamber. In the lower chamber MIP-1α was added. After 2, 5, and 24 hours, the DCs were counted in the lower chamber. (C-D) The expression of CCR1 on CML-DCs (solid lines) and DCs derived from healthy volunteers (dotted lines) was evaluated by staining with an anti-CCR1 mAb (thick lines) and isotype-matched mAb (thin lines). The results are representative of 11 experiments obtained with DCs derived from different patients as indicated in Table 1.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/101/9/10.1182_blood-2002-06-1841/4/h80934217008.jpeg?Expires=1735562850&Signature=WdphDWhDyFqC~TgSs-5KRuVE4iQBOdu6-iP1bzAfINI-wx2L4PN1zuxIuJzNwQEasKh2-bhjCD7GfWVUa0mLakkFALH6EjIc5CpOf8Mrkp7DhM7vVNlkzVwaWivAQ~S7Y1nL0LX4ixV0egoMfucJHpDVtNtSSwZUVTmXcu29k3Q7rGkY4muUdB~jYcq8yWsQwWFX~avu4inuYh57QmXaJu0A5ZtqYGAlERE2wvmG~UKggBbOySjJ58IXjMufkTiDslY7Z3ohUUUoL2m3S2GD2Lo5vjKg3tny24ikc-cvKmSEVzsrDPDJe9s3zvFpTDWi4jjf9IiGgYJqCTW2TJRA1w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Reduced capacity of CML-DCs to migrate.
DCs were generated from healthy individuals (■ [A-B]; dotted lines [C-D]) and from CML patients (▪ [A-B]; solid lines [C-D]): patient 1 (A,C) and patient 6 (B,D). (A-B) Immature DCs were added to the 8 μm pore size filter in a transwell cell culture chamber. In the lower chamber MIP-1α was added. After 2, 5, and 24 hours, the DCs were counted in the lower chamber. (C-D) The expression of CCR1 on CML-DCs (solid lines) and DCs derived from healthy volunteers (dotted lines) was evaluated by staining with an anti-CCR1 mAb (thick lines) and isotype-matched mAb (thin lines). The results are representative of 11 experiments obtained with DCs derived from different patients as indicated in Table 1.
